Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pharmacist phone calls could boost lifesaving statin use in heart patients

NCT ID NCT06551701

Disease control Sponsor: Duke University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests whether having a pharmacist call both patients with heart disease and their doctors can increase the use of high-intensity statins—powerful cholesterol-lowering drugs that prevent future heart problems. The trial includes adults aged 18 to 75 with atherosclerotic cardiovascular disease who are not already on a moderate or high-intensity statin. The goal is to see if this simple, low-cost intervention can improve medication use and reduce the risk of heart attacks and strokes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pharmacist-led intervention (calls to patients and providers)
What this could lead to
If successful, this approach could help more patients with heart disease get the recommended statin therapy, potentially reducing heart attacks and strokes.
What could go wrong
This is a small, early-stage trial focused on feasibility, not on directly measuring health outcomes. The intervention may not change prescribing habits or improve patient health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

225 people

The number who actually took part.

Started

May 2025

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes patients who have an ASCVD diagnosis but are currently not treated with a moderate-high intensity statin.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with a diagnosis of atherosclerotic cardiovascular disease currently not treated with a moderate- high intensity statin and the providers that care for them. * Patient age 18-75 Exclusion Criteria: * Hemodialysis * History of rhabdomyolysis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASCVD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerotic cardiovascular disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASCVD

Contacts and locations

Locations

  • Carelon Research

    Wilmington, Delaware, 19801, United States

  • Duke Clinical Research Institute

    Durham, North Carolina, 27701, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.